Kangfang Biological (9926freebonusnodepositrequired.HK) plunged nearly 45% to 26freebonusnodepositrequired.45 HKDfreebonusnodepositrequired, share price hits a new low since October 2022freebonusnodepositrequired, so far, the transaction volume has expanded to over HK$1.1 billion. It is reported that the Chinese Phase III clinical data of Kangfang Biotech AK112 and EGFR-TKi treated non-small cell lung cancer fell short of expectations.
It is also worth noting that the summary of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was officially released today. The TROP2-targeted antibody-conjugated drug (ADC)sacituzumab tirumotecan(SKB264/MK-2870), jointly developed by Merck (MSD) and Kelun-Biotech, has demonstrated outstanding results in a phase 3 trial in the treatment of advanced triple negative breast cancer (TNBC). Analysis showed that progression-free survival (PFS) of patients with high TROP2 expression who received SKB264 alone was more than three times that of patients in the chemotherapy group.
